Trial Profile
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Jun 2023 Primary endpoint has not been met (Progression-free survival (PFS)) , Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 19 Jul 2022 Status changed from suspended to active, no longer recruiting.